-
Posted by
Two Blokes Mon at 7:15 AM -
Filed in
Stock
-
2 views
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya\u00ae (somapacitan) was non-inferior to the once-daily growth hormone Norditropin\u00ae (somatropin) in improving yearly growth rate (as measured by height velocity [HV] at Week 52) in pre-pubertal children born small for gestational age (SGA)1, or with Noonan syndrome (NS)2, or with idiopathic short stature (ISS)3. In addition, superiority was achieved for once-weekly Sogroya\u00ae versus daily growth hormone in children with NS2, as well as compared to lower doses of daily growth hormone in children born SGA1.
